Matinas BioPharma Holdings Inc (MTNB) Short Interest Down 6.2% in November

Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) was the recipient of a large decrease in short interest during the month of November. As of November 30th, there was short interest totalling 1,873,864 shares, a decrease of 6.2% from the November 15th total of 1,998,494 shares. Based on an average trading volume of 173,935 shares, the short-interest ratio is currently 10.8 days. Currently, 2.6% of the shares of the stock are sold short.

Separately, ValuEngine cut shares of Matinas BioPharma from a “hold” rating to a “sell” rating in a research note on Wednesday, September 13th.

A hedge fund recently bought a new stake in Matinas BioPharma stock. Yellowstone Partners LLC purchased a new position in shares of Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 143,914 shares of the company’s stock, valued at approximately $190,000. Yellowstone Partners LLC owned about 0.16% of Matinas BioPharma at the end of the most recent reporting period.

Shares of Matinas BioPharma (MTNB) opened at $1.40 on Tuesday. Matinas BioPharma has a 12 month low of $1.01 and a 12 month high of $3.99.

Matinas BioPharma (NYSEAMERICAN:MTNB) last released its quarterly earnings results on Wednesday, November 15th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. Matinas BioPharma had a negative net margin of 7,558.92% and a negative return on equity of 195.09%. The company had revenue of $0.05 million for the quarter, compared to analysts’ expectations of $0.05 million.

ILLEGAL ACTIVITY NOTICE: This report was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at

About Matinas BioPharma

Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections.

Receive News & Ratings for Matinas BioPharma Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma Holdings Inc and related companies with's FREE daily email newsletter.

Leave a Reply